Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury

Table 10

Trials using SABR for renal cell carcinoma.

Trial	Remarks	Outcome
Wersäll et al. [89]	SABR for inoperable or metastatic RCC.	90–98% local control rate. Higher benefit for patients with ≤3 metastases.
Beitler et al. [90]	9 RCC patients (confined to kidney) refusing surgery. SABR 40 Gy in 5 Fc.	4 of 9 patients alive at median follow-up of 26.7 months. Curative potential of SABR in organ confined RCC established.
Svedman et al. [91]	7 RCC patients with single functioning kidney. SABR 30 Gy in 3 Fc.	Only 1 of 7 patients failed locally at follow-up of 54 months.
Siva et al. [92]	Systematic review of 3 prospective and 7 retrospective studies on use of SABR for primary RCC.	Derived LC rate of 93.9% and rate of severe toxicity (grade-3 or higher) of 3.8%.

LC: local control; RCC: renal cell carcinoma; Fc: fraction.